Belzutifan

贝组替凡

Report date: 2026/05/28 20:00:21
NMEFirst In Class

Base Information

Drug NameBelzutifan
Drug Alias NameWELIREG维利瑞MK-6482PT-2977
ClassificationSmall molecules
Mechanisms of ActionEndothelial PAS domain-containing protein 1 inhibitors
TargetsEndothelial PAS domain-containing protein 1
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursKidney Failure, Chronic +[25] 
Global Approved IndicationsPancreatic neuroendocrine tumors (pNET)von Hippel-Lindau DiseaseCentral Nervous System Neoplasms +[6] 
Approved Indications in ChinaPancreatic neuroendocrine tumors (pNET)von Hippel-Lindau DiseaseCentral Nervous System Neoplasms +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date2021/08/13
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPeloton Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteMsd International Gmbh T/A Msd Ireland (Ballydine)Merck Sharp & Dohme Corp +[9] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursKidney Failure, Chronic +[25] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XX74
Related LinksWikipediaDrugBankKEGG